GlassScriptPhysician profile
Shaminder Gupta
NPI 1730183401
$9,674.94
in general payments reported to CMS, 2019-2025
19 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $2,000 · 2021: $3,301 · 2022: $257 · 2023: $2,434 · 2024: $446 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,350 · Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,350.00 |
| Food and Beverage | $1,189.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quanta Dialysis Technologies INC | $4,000.00 | 2021-2023 | |
| Fresenius USA Marketing, INC. | $3,503.13 | 2020-2025 | Velphoro, Velphoro |
| Gastroklenz, INC. Dba Cloudcath | $434.00 | 2025 | |
| Aurinia Pharma U.S., INC. | $286.72 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $263.81 | 2019 | |
| Mallinckrodt Enterprises LLC | $157.54 | 2019 | |
| Vifor Pharma, INC. | $125.00 | 2023 | Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2023 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $116.04 | 2022 | |
| Calliditas Therapeutics US INC. | $103.35 | 2024 | |
| Amgen INC. | $101.66 | 2024 | Krystexxa |
| Akebia Therapeutics INC | $83.33 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.68 | 2021 | |
| Nxstage Medical, INC. | $73.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53.35 | 2022 | |
| Bard Peripheral Vascular, INC. | $25.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.98 | 2023 | |
| Travere Therapeutics, INC. | $8.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaminder Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.